Clinical Trial Detail

NCT ID NCT04332653
Title NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NeoImmuneTech
Indications

lung non-small cell carcinoma

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

Advanced Solid Tumor

colorectal cancer

Therapies

NT-I7 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.